Revelation Biosciences and Petra Acquisition today announced they have entered into a definitive merger agreement that values the combined enterprise at $128 million.
Terms call for Revelation to receive the $73 million of cash in Petra’s trust. Revelation’s existing stockholders will own approximately 54% of the fully diluted shares of common stock of the combined company if the deal is approved.
Revelation is a clinical stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease, paerticularly respiratory viruses. Read more.